{"id":7646,"date":"2024-03-19T11:04:34","date_gmt":"2024-03-19T03:04:34","guid":{"rendered":"https:\/\/flcube.com\/?p=7646"},"modified":"2024-10-18T11:30:09","modified_gmt":"2024-10-18T03:30:09","slug":"wuxi-apptec-posts-modest-revenue-growth-despite-regulatory-hurdles","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=7646","title":{"rendered":"WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles"},"content":{"rendered":"\n

WuXi AppTec (HKG: 2359<\/a>), a China-based Contract Research Organization (CRO), has released its financial results for 2023, reporting an annual operating revenue of RMB 40.34 billion (USD 5.6 billion), representing a year-on-year (YOY) increase of 2.5%. When excluding COVID-19-related commercial projects, sales experienced a substantial growth of 25.6%. The net profit attributable to the parent company reached RMB 9.61 billion (USD 1.33 billion), reflecting a 9.0% YOY rise, while operating cash flow surged by 23.6% to RMB 7.12 billion (USD 989 million).<\/p>\n\n\n\n

The company has recorded continuous growth in business volume and customer orders, with its WuXi Chemistry division increasing by 1.1% to RMB 29.17 billion in 2023. Excluding COVID-19 projects, this division showcased a remarkable growth rate of 36.1%. Other divisions performed as follows: WuXi Testing reported RMB 6.54 billion (+14.4%), WuXi Biology generated RMB 2.55 billion (+3.1%), and WuXi ATU (high-end CTDMO) achieved RMB 1.31 billion (+0.1%). However, revenue from domestic new drug research and development services fell to RMB 730 million, a decrease of 25.1% YOY.<\/p>\n\n\n\n

In terms of client engagement, WuXi AppTec added over 1,200 new customers in 2023, serving more than 6,000 active customers throughout the past year. Demand from overseas clients remained robust, with revenues from existing clients reaching RMB 39.63 billion (+30%) and new customer revenues totaling RMB 710 million. By year-end 2023, the company’s orders in hand, excluding COVID-19 projects, increased by 18% YOY. Revenue from the world\u2019s top 20 pharmaceutical companies grew impressively at a rate of 44% YOY to RMB 16.11 billion, while revenues from other global clients rose by 18% YOY to RMB 24.23 billion.<\/p>\n\n\n\n

Regionally, American clients remained the primary source of income, contributing RMB 26.13 billion, marking a 42% YOY increase and accounting for approximately 65% of revenue by Global Business Insights calculations. Revenue from European clients reached RMB 4.7 billion, a 12% increase, whereas revenues from Chinese clients were RMB 7.37 billion, up 1%. Clients from other regions brought in RMB 2.14 billion, representing an 8% growth.<\/p>\n\n\n\n

In light of recent US sanctions, WuXi AppTec has expressed concerns about its classification under the proposed US Biosafety Act, which labels it as a \u201cbiotech company of concern.\u201d The annual report emphasized the potential impact of this legislation on its ability to engage with customers tied to the US government. Despite external challenges, the company remains optimistic, projecting revenues for 2024 to reach between RMB 38.3 billion and RMB 40.5 billion.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[19,27,951,362],"class_list":["post-7646","post","type-post","status-publish","format-standard","hentry","category-company","tag-cro-cmo-cdmo","tag-finanical-reports","tag-hkg-2359","tag-wuxi-apptec"],"yoast_head":"\nWuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results for 2023, reporting an annual operating revenue of RMB 40.34 billion (USD 5.6 billion), representing a year-on-year (YOY) increase of 2.5%. When excluding COVID-19-related commercial projects, sales experienced a substantial growth of 25.6%. The net profit attributable to the parent company reached RMB 9.61 billion (USD 1.33 billion), reflecting a 9.0% YOY rise, while operating cash flow surged by 23.6% to RMB 7.12 billion (USD 989 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=7646\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=7646\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-19T03:04:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-18T03:30:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7646#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7646\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles\",\"datePublished\":\"2024-03-19T03:04:34+00:00\",\"dateModified\":\"2024-10-18T03:30:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7646\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"Finanical Reports\",\"HKG: 2359\",\"WuXi AppTec\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7646#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7646\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=7646\",\"name\":\"WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-03-19T03:04:34+00:00\",\"dateModified\":\"2024-10-18T03:30:09+00:00\",\"description\":\"WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results for 2023, reporting an annual operating revenue of RMB 40.34 billion (USD 5.6 billion), representing a year-on-year (YOY) increase of 2.5%. When excluding COVID-19-related commercial projects, sales experienced a substantial growth of 25.6%. The net profit attributable to the parent company reached RMB 9.61 billion (USD 1.33 billion), reflecting a 9.0% YOY rise, while operating cash flow surged by 23.6% to RMB 7.12 billion (USD 989 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7646#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7646\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7646#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles - Insight, China's Pharmaceutical Industry","description":"WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results for 2023, reporting an annual operating revenue of RMB 40.34 billion (USD 5.6 billion), representing a year-on-year (YOY) increase of 2.5%. When excluding COVID-19-related commercial projects, sales experienced a substantial growth of 25.6%. The net profit attributable to the parent company reached RMB 9.61 billion (USD 1.33 billion), reflecting a 9.0% YOY rise, while operating cash flow surged by 23.6% to RMB 7.12 billion (USD 989 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=7646","og_locale":"en_US","og_type":"article","og_title":"WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=7646","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-03-19T03:04:34+00:00","article_modified_time":"2024-10-18T03:30:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=7646#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=7646"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles","datePublished":"2024-03-19T03:04:34+00:00","dateModified":"2024-10-18T03:30:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=7646"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRO \/ CMO \/ CDMO","Finanical Reports","HKG: 2359","WuXi AppTec"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=7646#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=7646","url":"https:\/\/flcube.com\/?p=7646","name":"WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-03-19T03:04:34+00:00","dateModified":"2024-10-18T03:30:09+00:00","description":"WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results for 2023, reporting an annual operating revenue of RMB 40.34 billion (USD 5.6 billion), representing a year-on-year (YOY) increase of 2.5%. When excluding COVID-19-related commercial projects, sales experienced a substantial growth of 25.6%. The net profit attributable to the parent company reached RMB 9.61 billion (USD 1.33 billion), reflecting a 9.0% YOY rise, while operating cash flow surged by 23.6% to RMB 7.12 billion (USD 989 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=7646#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=7646"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=7646#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7646"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7646\/revisions"}],"predecessor-version":[{"id":7653,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7646\/revisions\/7653"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}